Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

EyePoint Pharmaceuticals (EYPT) EBITDA: 2010-2018

Historic EBITDA for EyePoint Pharmaceuticals (EYPT) over the last 8 years, with Sep 2018 value amounting to -$33.1 million.

  • EyePoint Pharmaceuticals' EBITDA fell 454.04% to -$33.1 million in Q3 2018 from the same period last year, while for Sep 2018 it was -$80.3 million, marking a year-over-year decrease of 364.05%. This contributed to the annual value of -$53.2 million for FY2018, which is 187.32% down from last year.
  • According to the latest figures from Q3 2018, EyePoint Pharmaceuticals' EBITDA is -$33.1 million, which was up 3.78% from -$34.4 million recorded in Q2 2018.
  • In the past 5 years, EyePoint Pharmaceuticals' EBITDA registered a high of $20.5 million during Q3 2014, and its lowest value of -$34.4 million during Q2 2018.
  • Its 3-year average for EBITDA is -$10.6 million, with a median of -$6.1 million in 2017.
  • As far as peak fluctuations go, EyePoint Pharmaceuticals' EBITDA surged by 666.34% in 2014, and later tumbled by 6,952.44% in 2017.
  • Quarterly analysis of 5 years shows EyePoint Pharmaceuticals' EBITDA stood at -$4.1 million in 2014, then fell by 26.39% to -$5.2 million in 2015, then surged by 98.43% to -$82,000 in 2016, then tumbled by 6,952.44% to -$5.8 million in 2017, then plummeted by 454.04% to -$33.1 million in 2018.
  • Its EBITDA was -$33.1 million in Q3 2018, compared to -$34.4 million in Q2 2018 and -$7.0 million in Q1 2018.